7-Hydroxymitragynine (7-OH): Pharmacology, Risks & Safety (2026 Review)
Evidence-based review of 7-hydroxymitragynine covering mu-opioid pharmacology, human PK data, concentrated product risks, FDA enforcement actions, and the critical distinction from traditional kratom leaf.
Important Safety Notice
This content is for educational purposes only and does not constitute medical advice. 7-Hydroxymitragynine (7-OH), especially in concentrated forms, carries risks of dependence, withdrawal, and respiratory depression. No FDA-approved drugs contain 7-OH. Concentrated 7-OH products are not lawful as dietary supplements or conventional foods. Consult a qualified healthcare professional before considering any substance.
What We Know — and What We Don't
What we know:
- 7-OH is a potent partial agonist at the mu-opioid receptor with significantly higher affinity than mitragynine [1]
- It is formed from mitragynine via CYP3A4 metabolism in humans [2]
- Concentrated 7-OH products have been associated with serious adverse events including respiratory depression and dependence
- The FDA recommended scheduling certain 7-OH products in July 2025, with enforcement actions including product seizures [4, 5]
- Traditional kratom leaf contains only trace amounts of 7-OH
What we don't know:
- No large, well-controlled human trials of isolated 7-OH exist
- The contribution of metabolite 7-OH to whole-leaf kratom effects is incompletely characterized
- Long-term safety data for concentrated products is absent
- Individual variability (genetics, tolerance, metabolism) is high and poorly quantified
The Critical Distinction: Leaf vs. Concentrated Products
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
| Traditional kratom leaf | Concentrated 7-OH products | |
|---|---|---|
| 7-OH content | Trace (<2% of alkaloids) | Significantly elevated (enriched or semi-synthetic) |
| Human data | Limited but growing (PK studies exist) | Very limited; mostly post-market surveillance |
| Dependence risk | Present | Potentially higher |
| Regulatory status | State-level restrictions vary | FDA has recommended scheduling; enforcement active |
| Evidence base | Includes human PK studies [2] | Mostly preclinical + adverse event reports |
These are not interchangeable products. Concentrated 7-OH is pharmacologically and toxicologically distinct from traditional kratom leaf.
Pharmacology
7-OH differs from mitragynine by a single hydroxyl group at the 7-position — a small structural change that produces dramatically higher mu-opioid receptor binding (Ki ~7–70 nM vs. much weaker affinity for mitragynine) [1]. In functional assays, 7-OH acts as a partial MOR agonist with higher efficacy than the parent compound.
Preclinical studies demonstrate dose-dependent antinociception — and classic opioid liabilities: respiratory depression, tolerance, physical dependence, and rewarding properties [6]. The CYP3A4-mediated metabolic pathway from mitragynine to 7-OH [2] means that CYP3A4 inhibitors, liver function, and polydrug use all affect exposure risk.
Human Evidence: The Gap
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
| Evidence type | Available for isolated 7-OH? | Available for whole leaf? |
|---|---|---|
| Cell / in vitro | Yes | Yes |
| Animal studies | Yes | Yes |
| Human PK studies | No | Yes [2] |
| Human RCTs | None | Limited |
| Long-term safety | None | None |
The bottom line: isolated 7-OH has no human clinical trial data. Claims about efficacy are based entirely on preclinical work and user reports. This evidence gap is enormous relative to the potency of the compound and the seriousness of documented adverse events.
Safety
Concentrated 7-OH products have been associated with respiratory depression, dependence, withdrawal, and — in post-market surveillance — cases involving polydrug use and severe outcomes. The FDA's risk assessment [3] and subsequent enforcement actions [4, 5] reflect the seriousness of these signals.
Elevated risk applies to anyone with: respiratory conditions, history of substance use disorder, concurrent CNS depressant use (alcohol, benzodiazepines, opioids, gabapentinoids), or compromised hepatic function (altered CYP3A4 metabolism).
Regulatory Status (June 2026)
- July 2025: FDA recommended scheduling certain 7-OH products under the Controlled Substances Act and issued warning letters to manufacturers
- December 2025: FDA participated in product seizures
- Current: Scheduling status subject to DEA review. State-level rules vary and change quickly. Verify current law before relying on any legal-status statement.
FAQ
Is 7-OH the same as kratom? No. It's one specific alkaloid present in trace amounts in natural leaf. Concentrated products are distinct.
Are there human clinical trials on pure 7-OH? None have been published as of June 2026.
Why has the FDA acted on 7-OH? Cited safety concerns including dependence and respiratory depression. Determined concentrated 7-OH products are not lawful as dietary supplements.
Is traditional kratom leaf the same as concentrated 7-OH? No. Traditional leaf contains trace 7-OH within a complex alkaloid matrix. Concentrated products deliver much higher 7-OH levels directly, with a distinct risk profile.
Educational purposes only. Does not replace professional medical advice.
References
- Obeng S, et al. In Vitro Affinity and Efficacy for mu-Opioid Receptor and Other Targets of Mitragynine and 7-Hydroxymitragynine (2021) — Source
- Huestis MA, et al. Human Mitragynine and 7-Hydroxymitragynine Pharmacokinetics after Single and Multiple Daily Doses of Oral Encapsulated Dried Kratom Leaf Powder (2024) — Source
- U.S. Food and Drug Administration 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat (2025) — Source
- U.S. Food and Drug Administration FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers (2025) — Source
- U.S. Food and Drug Administration FDA Seizes 7-OH Opioids to Protect American Consumers (2025) — Source
- Kruegel AC, et al. 7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects (2019) — Source